Cancer Network - Melanoma | For Oncologists
323 FOLLOWERS
Updates for oncologists on melanoma screening, diagnosis (ABCDEs), and treatment using BRAF and MEK inhibitors, anti-PD-1 and PD-L1 antibodies, and other therapies.
Cancer Network - Melanoma | For Oncologists
5d ago
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma ..read more
Cancer Network - Melanoma | For Oncologists
3w ago
mRNA-4157 is being evaluated in combination with pembrolizumab as part of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial in patients with completely resected, high-risk, stage III to IV melanoma ..read more
Cancer Network - Melanoma | For Oncologists
3w ago
Patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody can now receive lifileucel after accelerated approval from the FDA ..read more
Cancer Network - Melanoma | For Oncologists
2M ago
Treatment Algorithms with the Oncology Brothers ..read more
Cancer Network - Melanoma | For Oncologists
3M ago
Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma ..read more
Cancer Network - Melanoma | For Oncologists
6M ago
Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors ..read more
Cancer Network - Melanoma | For Oncologists
6M ago
Nivolumab is now available as an adjuvant treatment for patients with completely resected stage IIB or IIC melanoma following its approval by the FDA based on data from the phase 3 CheckMate-76k trial ..read more
Cancer Network - Melanoma | For Oncologists
7M ago
Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points ..read more
Cancer Network - Melanoma | For Oncologists
8M ago
Data from the phase 3 CheckMate-76k trial support the European Commission’s approval of nivolumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma ..read more
Cancer Network - Melanoma | For Oncologists
8M ago
Supporting data for the FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study ..read more